Stockholder Overview

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Since we began operations in November 2014, we have built a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. ... 

NASDAQ CRVS (Common Stock)
$14.45 - 0.29 (1.97%)
10/21/164:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart

Stock chart for: CRVS.O.  Currently trading at $14.45 with a 52 week high of $17.77 and a 52 week low of $9.63.